Interpreting Parietal Cell Antibody (PCA) Testing for Autoimmune Gastritis

Test Sensitivity and Clinical Correlation

• PCA is the most sensitive serum biomarker for autoimmune gastritis, detecting antibodies in 85‑90 % of patients with pernicious anemia; however, results must be correlated with clinical findings and confirmed histologically because false‑positive results are common in Helicobacter pylori infection and other autoimmune diseases. 1

Diagnostic Algorithm

Step 1 – Combine PCA with Intrinsic Factor Antibody (IFA)

• When both PCA and IFA are positive, there is a high likelihood of autoimmune gastritis. 2
• If only PCA is positive, further evaluation (e.g., H. pylori testing, histology) is required. 1

Step 2 – Exclude H. pylori Infection

• All patients with a positive PCA should be tested for H. pylori using non‑serological methods such as stool antigen or urea breath test. 1
• H. pylori infection is a common cause of false‑positive PCA; therefore, it must be ruled out before attributing positivity to autoimmune gastritis. 1
• If H. pylori is detected, eradication therapy should be completed and PCA retested after successful eradication to determine whether the antibody positivity persists. 1

Step 3 – Histologic Confirmation (United States)

• Histopathology is mandatory for a definitive diagnosis of autoimmune gastritis in the United States. [1][2]
• The updated Sydney protocol should be used, obtaining five biopsies in separate jars:
  All biopsy location recommendations are based on the same source. 1
• Autoimmune gastritis characteristically shows corpus‑predominant atrophy with sparing of the antrum, a key histologic pattern that aids diagnosis. 3

Common Pitfalls (Evidence‑Based Recommendations)

• Do not diagnose autoimmune gastritis on PCA alone; histologic confirmation is required because of the high false‑positive rate associated with PCA testing. [1][2]
• Do not omit H. pylori testing in the work‑up of a PCA‑positive patient, as untreated infection can mimic or mask autoimmune gastritis. 1

All statements are derived from peer‑reviewed evidence (Gastroenterology, 2021; Gut, 2019) and reflect current best‑practice recommendations.

Gastritis Treatment Guidelines

Diagnosis and Classification

• Gastritis should be confirmed by histopathology, with biopsies from both the gastric body and antrum/incisura, as recommended by the American Gastroenterological Association 4, 5
• All patients with gastritis should be assessed for H. pylori infection using non-serological testing modalities, according to the European Helicobacter Study Group 4, 6
• Two main etiologies of gastritis are H. pylori infection and autoimmunity, as identified by the American Gastroenterological Association 4, 7

Treatment Algorithm

• For H. pylori-positive gastritis, eradication therapy is the cornerstone of treatment, with bismuth quadruple therapy recommended as first-line treatment due to increasing clarithromycin resistance, as suggested by the American College of Gastroenterology 8, 6
• Concomitant 4-drug therapy is an alternative when bismuth is not available, according to the European Helicobacter Study Group 8
• Successful eradication should be confirmed using non-serological testing, as recommended by the American Gastroenterological Association 4, 6

Special Considerations

• For patients with autoimmune gastritis, consider checking antiparietal cell antibodies and anti-intrinsic factor antibodies, as recommended by the American Gastroenterological Association 4, 9
• Screen for type 1 gastric neuroendocrine tumors with upper endoscopy, according to the European Neuroendocrine Tumor Society 4, 10
• Evaluate for iron and vitamin B-12 deficiencies, especially if corpus-predominant, as suggested by the American Gastroenterological Association 4, 7
• Consider endoscopic surveillance every 3 years for advanced atrophic gastritis, as recommended by the American College of Gastroenterology 4, 11

Prevention Strategies

• H. pylori eradication reduces the risk of gastric cancer development, especially before the development of preneoplastic conditions, as suggested by the International Agency for Research on Cancer 6, 12
• Risk stratification of patients with premalignant gastric conditions should be based on the severity and distribution of lesions, according to the European Helicobacter Study Group 12
• Patients with risk factors for gastric cancer should be considered for H. pylori eradication even if asymptomatic, as recommended by the American College of Gastroenterology 12

Diagnosis and Management of Autoimmune Gastritis with Positive Parietal Cell Antibody (PCA) Titer > 24

1. Initial Laboratory Evaluation

• Obtain a complete blood count to screen for anemia in patients with elevated PCA. 13
• Measure serum vitamin B12 levels regardless of anemia status to detect early deficiency. 13
• Assess iron studies (serum iron and ferritin) because iron deficiency frequently co‑exists with B12 deficiency in atrophic gastritis. 13

2. Endoscopic Confirmation

2.1 Biopsy Protocol

• Perform upper endoscopy using the updated Sydney protocol: acquire five topographically‑guided biopsies placed in two separate jars (antrum/incisura jar = 2 antral biopsies + 1 incisura; body/corpus jar = 2 corpus biopsies). 13

2.2 Endoscopic Findings

• Look for pale gastric mucosa, loss of rugal folds, and prominent submucosal vessels—features suggestive of corpus‑predominant atrophy. 13

2.3 Histologic Hallmark

• Identify corpus‑predominant atrophy with antral sparing as the characteristic histologic pattern of autoimmune gastritis. 13

2.4 Ancillary Assessments During Endoscopy

• Test biopsy specimens for Helicobacter pylori when non‑invasive testing has not been performed. 13
• Inspect for gastric neuroendocrine tumors (NETs), which may appear as small polyps in the setting of autoimmune gastritis. 13
• Use narrow‑band imaging (NBI) to detect intestinal metaplasia, recognizing the light‑blue‑crest (LBC) and white‑opaque‑substance (WOS) signs. 13

3. Screening for Associated Autoimmune Disorders

• Screen for autoimmune thyroid disease; PCA positivity occurs in approximately 18–21 % of patients with thyroid autoimmunity. 13
• Consider evaluation for type 1 diabetes mellitus based on clinical presentation, as it is another common comorbidity. 13

4. Surveillance Strategy

• Schedule surveillance endoscopy every 3 years in patients with confirmed advanced atrophic gastritis, owing to the heightened risk of gastric adenocarcinoma and neuroendocrine tumors. 13

5. Nutritional Replacement

• Replace iron when deficiency is documented to address concurrent iron‑deficiency anemia. 13